Drug Trial Radar · NCT06345404
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Apr 16, 2024
Primary completion
Jan 28, 2026
Study completion Feb 24, 2026
Sponsor
- Lead sponsor
- Corvus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Conditions
- Atopic Dermatitis
Interventions
SoquelitinibDrug
Tablets
PlaceboDrug
Soquelitinib matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiogramsTime frame: Up to 30 days after last intervention administration
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 5
Birmingham, Alabama
Clinical Site 9
Tucson, Arizona
Clinical Site 3
North Little Rock, Arkansas
Clinical Site 2
Fremont, California
Clinical Site 7
Palo Alto, California
Clinical Site 13
Pomona, California
Clinical Site 10
Castle Rock, Colorado
Clinical Site 6
Tampa, Florida
Clinical Site 11
Brooklyn, New York
Clinical Site 16
New York, New York
Clinical Site 12
New York, New York
Clinical Site 15
Mayfield Heights, Ohio
Clinical Site 1
Camp Hill, Pennsylvania
Clinical Site 8
Philadelphia, Pennsylvania
Clinical Site 4
Frisco, Texas
Clinical Site 14
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.